IRC- and investigator-assessed best response in patients with r/r MCL
| Response assessment . | IRC-assessed response . | Investigator-assessed response . |
|---|---|---|
| No. of patients | 106 | 106 |
| Median follow-up (mo) | 23.8 | 23.8 |
| ORR (%) | 81.1 (72.4-88.1) | 82.1 (73.4-88.9) |
| CR | 27.4 | 34.9 |
| PR | 53.8 | 47.2 |
| SD | 5.7 | 5.7 |
| DCR (%) | 86.8 (78.8-92.6) | 87.7 (79.9-93.3) |
| PD | 8.5 | 5.7 |
| Response assessment . | IRC-assessed response . | Investigator-assessed response . |
|---|---|---|
| No. of patients | 106 | 106 |
| Median follow-up (mo) | 23.8 | 23.8 |
| ORR (%) | 81.1 (72.4-88.1) | 82.1 (73.4-88.9) |
| CR | 27.4 | 34.9 |
| PR | 53.8 | 47.2 |
| SD | 5.7 | 5.7 |
| DCR (%) | 86.8 (78.8-92.6) | 87.7 (79.9-93.3) |
| PD | 8.5 | 5.7 |
Response data are expressed as the percentage (95% CI).
DCR, disease control rate; ORR, overall response rate; PD, progressive disease; SD, stable disease.